Trial · NCT05366062
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
NCT05366062, Phase 2, Unknown, Epitopoietic Research Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab. Trials, record NCT05366062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05366062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
- NCT number
- NCT05366062
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 28 participants, estimated
- Lead sponsor
- Epitopoietic Research Corporation
- Conditions
- Glioma, Malignant
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Pembrolizumab
- First posted
- 2022-05-09
- Last updated
- 2022-05-13
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival at 12 months | 12 months | Overall Survival at 12 months as assessed per iRANO Criteria. |
| Secondary | Progression-free survival | 12 Months | Dates from date of first injection of vaccine. |
| Secondary | Radiographic Response | 12 Months | Radiographic Response, categorized per iRANO Criteria. |
| Secondary | Number of participants with Adverse Events [Safety and Tolerability] | 12 months | As indicated by the number and rate of adverse events, categorized by the CTCAE v. 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05366062
GET https://conductscience.org/api/trials/v1/NCT05366062/registered